cyc 202 has been researched along with Infections, Pseudomonas in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berre, RL; Chiron, R; Danner-Boucher, I; Durieu, I; Fajac, I; Hery-Arnaud, G; Hillion, S; Hubert, D; Huge, S; Leroy, S; Leven, C; Macey, J; Meijer, L; Mottier, D; Murris-Espin, M; Nowak, E; Prevotat, A; Rault, G; Ravoninjatovo, B; Renaudineau, Y; Urban, T | 1 |
| Burgel, PR; Marteyn, BS; Meijer, L; Witko-Sarsat, V | 1 |
1 review(s) available for cyc 202 and Infections, Pseudomonas
| Article | Year |
|---|---|
Harnessing Neutrophil Survival Mechanisms during Chronic Infection by
Topics: Animals; Anti-Bacterial Agents; Apoptosis; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Hypoxia; Immunity, Innate; Infections; Inflammation; Lung; Lung Diseases; Macrophages; Mice; Neutrophils; Pseudomonas aeruginosa; Pseudomonas Infections; Purines; Roscovitine; Virulence | 2017 |
1 trial(s) available for cyc 202 and Infections, Pseudomonas
| Article | Year |
|---|---|
Safety and pharmacokinetics of Roscovitine (Seliciclib) in cystic fibrosis patients chronically infected with Pseudomonas aeruginosa, a randomized, placebo-controlled study.
Topics: Animals; Cystic Fibrosis; Double-Blind Method; Humans; Protein Kinase Inhibitors; Pseudomonas aeruginosa; Pseudomonas Infections; Quality of Life; Roscovitine | 2022 |